Evidence map›Paper›PMID 39308640›Full record

ArticleEuropean urology open science2024

First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Stefanie Fischer, Silke Gillessen, Odile Stalder, Angelika Terbuch, Richard Cathomas, Florian A Schmid, Deborah Zihler, Beat Müller, Christian D Fankhauser, Anita Hirschi-Blickenstorfer and 14 more

Abstract read
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Stefanie FischerDepartment of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Silke GillessenOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Odile StalderDepartment of Clinical Research, CTU Bern, University of Bern, Bern, Switzerland.
Angelika TerbuchDivision of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, Austria.
Richard CathomasDivision of Medical Oncology/Haematology, Cantonal Hospital Graubünden, Chur, Switzerland.
Florian A SchmidDepartment of Urology, University Hospital Zurich, Zurich, Switzerland.
Deborah ZihlerDepartment of Medical Oncology and Haematology, Cantonal Hospital Aarau, Aarau, Switzerland.
Beat MüllerDepartment of Medical Oncology, Cantonal Hospital Luzern, Luzern, Switzerland.
Christian D FankhauserDepartment of Urology, Cantonal Hospital Luzern, Luzern, Switzerland.
Anita Hirschi-BlickenstorferOnkozentrum Hirslanden, Clinic Hirslanden, Zurich, Switzerland.
Luis Alex KluthDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Bettina SeifertDepartment of Medical Oncology, Cantonal Hospital Liestal, Basel, Switzerland.
Arnoud J TempletonDepartment of Medical Oncology, St. Claraspital/St. Clara Research and Faculty of Medicine, University of Basel, Basel, Switzerland.
Walter MingroneDepartment of Medical Oncology, Cantonal Hospital Olten, Olten, Switzerland.
Mark-Peter UfeAmmerland Klinik, Westerstede, Germany.
Natalie FischerDepartment of Medical Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
Jörg BeyerDepartment of Medical Oncology, University Hospital Bern, Bern, Switzerland.
Regina WoelkyDepartment of Medical Oncology, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland.
Aurelius OmlinOnkozentrum Zurich und Uro-Onkologisches Zentrum, Hirslanden Klinik Zurich, Zurich, Switzerland.
Ursula VoglOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Katharina HoppeStadtspital Triemli Zurich, Zurich, Switzerland.
Jörn KamradtUrologie Zentrum Bern und Hirslanden Bern, Bern Switzerland.
Sacha I RothschildDepartment of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Basel, Switzerland.
Christian RothermundtDepartment of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Follow-up for patients with testicular cancer should ensure early detection of relapses. Optimal schedules and minimum requirements for cross-sectional imaging are not clearly defined, and guideline recommendations differ. Our aim was to analyse the clinical impact of different imaging modalities for detection of relapse in a large prospective cohort (Swiss Austrian German Testicular Cancer Cohort Study, SAG TCCS). Methods: Patients with seminoma or nonseminoma were prospectively enrolled between January 2014 and February 2023 after initial treatment ( Key findings and limitations: We analysed data for 1006 patients (64% seminoma, 36% nonseminoma); 76% had stage I disease. Active surveillance was the most frequent management strategy (65%). Recurrence occurred in 82 patients, corresponding to a 5-yr relapse-free survival rate of 90.1% (95% confidence interval 87.7-92.1%). Median follow-up for patients without relapse was 38.4 mo (interquartile range 21.6-61.0). Cross-sectional imaging of the abdomen was the most important indicator of relapse 57%, abdominal CT accounting for 46% and MRI for 11%. Marker elevation indicated relapse in 24% of cases. Chest X-ray was the least useful modality, indicating relapse in just 2% of cases. Conclusions and clinical implications: On the basis of findings from our prospective register, we have adapted a follow-up schedules with an emphasis on abdominal imaging and a reduction in chest X-rays. This schedule might provide additional guidance for clinicians and will be prospectively evaluated as SAG TCCS continues to enrol patients. Patient summary: We analysed the value of different types of imaging scans for detection of relapse of testicular cancer. We used our findings to propose an optimum follow-up schedule for patients with testicular cancer.

Indexed as

Follow-upGerm cell tumoursTesticular cancer

Identifiers

PMID39308640
PMCPMC11416594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.